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http:WHAT THIS PAPER ADDS
This study contributes to the debate surrounding the treatment of ruptured aorto-iliac aneurysms by endo-
vascular or open surgical repair.Objectives/Background: ECAR (Endovasculaire ou Chirurgie dans les Anévrysmes aorto-iliaques Rompus) is a
prospective multicentre randomized controlled trial including consecutive patients with ruptured aorto-iliac
aneurysms (rAIA) eligible for treatment by either endovascular (EVAR) or open surgical repair (OSR). Inclusion
criteria were hemodynamic stability and computed tomography scan demonstrating aorto-iliac rupture.
Methods: Randomization was done by week, synchronously in all centers. The primary end point was 30 day
mortality. Secondary end points were post-operative morbidity, length of stay in the intensive care unit (ICU),
amount of blood transfused (units) and 6 month mortality.
Results: From January 2008 to January 2013, 107 patients (97 men, 10 women; median age 74.4 years) were
enrolled in 14 centers: 56 (52.3%) in the EVAR group and 51 (47.7%) in the OSR group. The groups were similar in
terms of age, sex, consciousness, systolic blood pressure, Hardman index, IGSII score, type of rupture, use of
endoclamping balloon, and levels of troponin, creatinine, and hemoglobin. Delay to treatment was higher in the
EVAR group (2.9 vs. 1.3 hours; p < .005). Mortality at 30 days and 1 year were not different between the groups
(18% in the EVAR group vs. 24% in the OSR group at 30 days, and 30% vs. 35%, respectively, at 1 year). Total
respiratory support time was lower in the EVAR group than in the OSR group (59.3 hours vs. 180.3 hours;
p ¼ .007), as were pulmonary complications (15.4% vs. 41.5%, respectively; p ¼ .050), total blood transfusion
(6.8 vs. 10.9, respectively; p ¼ .020), and duration of ICU stay (7 days vs. 11.9 days, respectively; p ¼ .010).
Conclusion: In this study, EVAR was found to be equal to OSR in terms of 30 day and 1 year mortality. However,
EVAR was associated with less severe complications and less consumption of hospital resources than OSR.
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The post-operative mortality after open surgical repair
(OSR) of ruptured aorto-iliac aneurysms (rAIA) and the
feasibility of endovascular repair (EVAR) of asymptomatic
abdominal aortic aneurysms (AAAs) have lead to the
consideration of EVAR for rAIA as an alternative to OSR, and
as the ﬁrst line therapy in most centers.1e5 In a recent
meta-analysis of observational studies and registries, EVAR
was associated with a 50% risk reduction in mortality.6
These encouraging results are considered sufﬁcient by
“endo-enthusiasts”, but patients suitable for EVAR are
usually selected because of hemodynamic stability and
aneurysm morphology. The “endo-skeptics” thus argue that
patient selection, as most of the patients at risk of post-
operative complications are treated by OSR, plays an
overly important role and await the results of randomized
multicenter studies.7
To compare EVAR with OSR for rAIAs in homogeneous
groups of patients, a multicenter randomized trial, ECAR
(Endovasculaire ou Chirurgie dans les Anévrysmes aorto-
iliaques Rompus), was conducted.8 Two major re-
quirements had to be fulﬁlled: (i) the patients had to be
hemodynamically stable; and (ii) pre-operative computed
tomography angiography (CTA) had to prove aortic rupture
and document favorable anatomy.
METHODS
The study was registered at clinicaltrials.gov (https://www.
clinicaltrials.gov/ct2/show/NCT00577616).Study design
ECAR is a prospective, multicenter (14 centers), randomized
(per week) controlled trial (RCT) in which all patients pre-
senting with a rAIA amenable to both methods (OSR and
EVAR) were included. The study was approved by the
Counsel for the Protection of Persons Volunteering for
Biomedical Research, Ile de France, in July 2007.
Because of the emergency context, informed consent was
only obtained from survivors. The unit of randomization was
the week (synchronous for all centers): patients were
treated by OSR during the ﬁrst week and subsequent odd
numbered weeks, and by EVAR during the second week and
subsequent even numbered weeks. A reminder of the
treatment for the week was sent to all centers by automatic
email and fax each Monday at 8.30 a.m. All patients with
rAIA not enrolled in the study were listed in a non-inclusion
registry for each center.Study end points
The primary end point was to compare the mortality rate of
the two groups at 30 days after treatment.
The secondary end points were 30 day post-operative
morbidity (cardiac, pulmonary, digestive, renal, and neuro-
logical), duration of stay in the intensive care unit (ICU),
amount of blood transfused (units), in hospital mortality,
and 6 month and 1 year mortality and morbidity rates.Complications were reported according to the guidelines
of the Society for Vascular Surgery/International Society of
Cardiovascular Surgery.9 Clinical, biological tests and radio-
logical follow up were performed at 48 hours, 30 days, 6
months, and 1 year after intervention. At regular intervals, a
committee for the validation of critical events evaluated all
serious and undesirable events. In the event of an imbal-
ance in serious undesirable events between the two arms,
an independent monitoring committee could recommend
interruption of the trial. All data were collected in a case
report form and were available at the time of the usual
assumption of responsibility of these patients. A registry of
all treated rAIAs documented the number of patients not
enrolled in the study during the same period.
A cost analysis was also carried out, which reported costs
(V, 2010) according to the French National Health system.
The cost of the hospital stay of an individual patient corre-
sponds to a homogenous group of patients (HGP), similar to
Medicare Diagnosis Related Groups. Patients treated by OSR
are in a different HGP than patients treated by EVAR, for
whom the mean cost of the stent-graft (V3,981) was added
to theHGP. According to patients’ comorbidities, aweight risk
adjustment was done according to the OSR group case mix.
Patient selection, and inclusion, and exclusion criteria
Inclusion criteria. Inclusion criteria included a rAIA (i.e.,
ruptured aortic, aorto-iliac, or iliac aneurym) documented
by pre-operative CTA. Aneurysm rupture was deﬁned by the
existence of blood outside of the aorto-iliac aneurysm
arterial wall: (i) retroperitoneal hematoma with peri-aortic
blood in the peri-renal space and/or the para-renal space;
or (ii) intraperitoneal hematoma. Arteriovenous ﬁstulae to
the inferior vena cava (IVC)/iliac vein and aortoenteric ﬁs-
tula were eligible criteria for the study, whereas contained
or impending ruptures such as hemorrhage into a mural
thrombus were not considered eligible. Patients had to be
clinically and anatomically suitable to both OSR and EVAR.
They also had to be hemodynamically stable, which was
deﬁned as a systolic blood pressure (SBP) on arrival
>80 mmHg, in the absence of the need for continuous
intravenous infusion and catecholamine administration in
high dosage. The ﬁnal inclusion criterion was the availability
of a qualiﬁed surgeon (with minimum prerequisite of having
carried out 15 EVAR procedures for asymptomatic/symp-
tomatic AAA) and of devices and facilities for performing
EVAR.
Intervention
Hemodynamically stable patients with a suspected diag-
nosis of rAIA were transferred to the CT suite. Other pa-
tients were referred with an initial CTA. Once rupture was
conﬁrmed, and if the inclusion criteria were met, the pa-
tient was operated on according to the treatment allocated
for that week.
In the event of unstable hemodynamic status
(SBP < 80 mmHg), a direct to theatre procedure for OSR
was carried out and the patient was not included in the
Table 1. Pre-operative assessment of both groups of patients included in the ECAR trial.
OSR (n ¼ 51) EVAR (n ¼ 56) p
Mean age (years) 73.8 (54.0e93.0) 75.0 (56.0e96.0) .548
Sex (male), n (%) 46 (90.0) 51 (91.0) .877
Height (cm) 175 (164e187) 172 (150e190) .052
Weight (kg) 78.5 (55.0e117.0) 77.1 (50.0e125.0) .630
SBP (mean mmHg) 110.9 105.9 .393
Endoclamping balloon, n (%) 11 (21.6) 7 (12.5) .210
Loss of consciousness, n (%) 6 (11.8) 6 (10.8) .863
Retroperitoneal rupture, n (%) 49 (96) 51 (91.0) .335
Hardman index 1.1 (0e5) 1.0 (0e3.0) .880
IGSII score 40.1 (18.0e82.0) 35.9 (0e83.0) .128
Creatinine level (mmol/L) 123.7 (57.0e309.0) 137.5 (56.0e584.0) .355
Hemoglobin level (g/dl) 10.6 (5.0e140.0) 13.5 (6.0e85.0) .450
Troponin level 0.7 (0e15.0) 0.3 (0e4.8) .386
Abnormal ECG, n (%) 9 (18) 10 (11) 1.000
Delay to treatment (h) 1.3 (0e5.5) 2.9 (0.2e17.0) .005
Note.Values are given as mean (range) unless otherwise indicated. ECAR¼ Endovasculaire ou Chirurgie dans les Anévrysmes aorto-iliaques
Rompus; OSR ¼ open surgical repair; EVAR ¼ endovascular aneurysm repair; SBP ¼ systolic blood pressure; ECG ¼ electrocardiogram.
A French Randomized Controlled Trial of Endovascular 305study. However, aortic endoclamping could be attempted.10
Once a stable hemodynamic status has been obtained for
10 minutes, inclusion in the study was considered. In all
cases, SBP was maintained between 80 and 100 mmHg.
OSR. In order to avoid sudden hypotension due to the
relaxation of the abdominal wall, no general anesthesia was
administered until the patient was prepped and draped. The
level of aortic cross-clamping was left to the operator’s
preferences (infra or suprarenal via a median laparotomy or
thoracic via a left anterolateral thoracotomy), and aortic
replacement was performed with a standard tube or
bifurcated graft in the usual way. A retroperitoneal
approach could be carried out in the event of previous
laparotomy or of rupture in the IVC.
EVAR. Insertion of the endoprosthesis was performed un-
der the same conditions as for asymptomatic AAA. Ac-
cording to the operator’s preference, two types of devices
could be inserted: (1) an aorto-uni-iliac stent graft com-
bined with occlusion of the contralateral iliac artery, fol-
lowed by a femoro-femoral crossover bypass; or (ii) a
bifurcated aorto-bi-iliac stent graft.
EVAR was always performed within the instructions for
use. Endoprostheses were Zenith (Cook Medical, Bloo-
mington, IN, USA) and Talent (Medtronic, Minneapolis, MN,
USA) aorto-uniiliac devices, or Excluder (WL Gore, Newark,
DE, USA), Zenith TriFab (Cook), and Talent (Medtronic)
bifurcated devices. Other more recent endoprostheses were
allowed for the study provided they had been authorized
for at least 1 year for treating asymptomatic AAA.Statistical analysis
The sample size calculation of this superiority study was
based on the primary efﬁcacy variable: mortality at 30 days.
The principal hypothesis was that EVAR would decrease the
mortality by 20%. The expected mortality of patients pre-
senting with a ruptured aneurysm of the abdominal aorta
treated by OSR within the framework of this study was 40%.To achieve a power >80% with an alpha risk of 5%, 80
patients were required in each treatment group. The risk of
losing patients to follow up at 30 days was minimal. It was
initially the intention to include a total of 160 patients. In
the end, only 107 patients were included because of the
end of the trial after 5 year enrolment.
All variables were described at baseline and during follow
up. Results were expressed as mean and SD for continuous
variables and as a percentage for discontinuous variables.
Description of the two groups on inclusion, comparison of
30 day mortality and survival without event (morbidity/
mortality) rates were carried out in an intention to treat
protocol according to a pre-speciﬁed analysis plan. Cate-
gorical parameters were compared between groups by chi-
square test. Continuous parameters were compared after
checking their distribution by a variance analysis or non-
parametric test. Mixed model regression was used in
multivariate analysis. Comparison of 30 day survival without
event (morbidity/mortality) was performed using the
KaplaneMeier method with log rank test in univariate
analysis and the Cox model for multivariate analysis.
Exploratory subgroup analysis was performed according to
previous results. A Cox score was drawn from variables
identiﬁed by multivariate analysis of factors inﬂuencing 30
day mortality.RESULTS
Enrolment
Between January 2008 and January 2013 107 patients with
a rAIA, presenting at the 14 participating centers, were
included. Fifty-six patients (52.3%) were included in the
EVAR group and 51 (47.7%) in the OSR group. Groups were
similar in terms of age, sex, consciousness, SBP, Hardman
index, IGSII score, type of rupture, use of endoclamping
balloon, and levels of troponin, creatinine, and hemoglobin
(Table 1). Delay to treatment was longer in the EVAR group
(2.9 vs. 1.3 hours; p < .005).
Figure 1. CONSORT ﬂow chart of the ECAR trial. Note.
EVAR ¼ endovascular aneurysm repair; OSR ¼ open surgical
repair; ECAR ¼ Endovasculaire ou Chirurgie dans les Anévrysmes
aorto-iliaques Rompus.
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As described by the CONSORT diagram in Fig. 1, during the
5 year study period, 417 patients operated on for rAIA but
not enrolled in ECAR study (116 EVAR and 301 OSR) were
recorded. The suitability rate (32.8%) for EVAR was calcu-
lated by dividing the overall number of patients treated by
EVAR (56 randomized and 116 not randomized) by the
overall number of patients treated in the 14 centers. Fig. 2
shows the variability of treatments amongst centers.CTA
The CT ﬁndings showed that the rupture was aortic in 102
cases and iliac in ﬁve: mean diameters were 79.1 mm (range
43.0e140.0 mm) and 77.8 mm (range 55.0e90.0), respec-
tively. Visceral artery occlusion was seen in six patients: oneFigure 2. Type of intervention carried out in 14 centers participating in
to January 2013. Note. EVAR ¼ endovascular aneurysm repair; OSR ¼
Anévrysmes aorto-iliaques Rompus.renal artery occlusion and ﬁve patients at risk of colonic
ischemia (two bilateral occlusions of internal iliac arteries
[IIAs], two occlusions of one IIA and inferior mesenteric
artery [IMA], one occlusion of both IIA). Thirty-seven addi-
tional patients had occlusion of the IMA alone. Mean
proximal neck length and diameter were 29.0  22.8 and
23.8  4.5 mm, respectively. Mean angulation of the aortic
neck was 33.5  25.6. Peripheral occlusive arterial disease
(i.e., signiﬁcant iliac and/or femoropopliteal stenoses or
occlusions) was present in 13.1% patients.
CT ﬁndings were retroperitoneal hematoma in 100 pa-
tients (93.5%), intraperitoneal hematoma in four (3.7%),
and arteriovenous (IVC or iliac) or aortoenteric ﬁstulas in
three (2.8%). CT ﬁndings were comparable between groups
(p ¼ .335).
Hemodynamic stability
Eighty nine (83.2%) patients were hemodynamically stable
on arrival, and in 18 patients (16.8%) initial hemodynamic
instability was corrected by endovascular balloon occlusion.
Procedural data
Time from admission to treatment was longer in the EVAR
group (2.9 vs. 1.3 hours; p < .005). Operative time (skin to
skin) was similar between the OSR (3.4 hours; range 1.33e
6.5 hours) and EVAR groups (3.2 hours; range 1.5e11
hours). In the OSR group, the level of clamping was thoracic
in two cases (4%), suprarenal in eight (15.7%), and
infrarenal in 41 (80.3%), with a mean time to clamping of 9
minutes. Bypasses were aorto-aortic (n ¼ 27), bifurcated
(n ¼ 22), or axillo-bifemoral (after ligation of the infrarenal
aorta; n ¼ 1). One patient died before aortic replacement,
and three additional patients died intra-operatively (two
hemorrhagic shock, one multi-organ failure).the ECAR trial (including non-enrolled patients) from January 2008
open surgical repair; ECAR ¼ Endovasculaire ou Chirurgie dans les
Table 2. Causes of death of patients included in the ECAR trial.
EVAR
(n ¼ 56)
OSR
(n ¼ 51)
Overall
(n ¼ 107)
Intra-operative 1 4 5
MOF 1
Hemorrhage 1 3
Post-operative 12 (10) 14 (8) 26 (18)
In hospital
Compartment syndrome 4 (4) 0
MOF 1 (1) 5 (4)
Sepsis 2 (1) 2 (1)
ARDS 0 2
Colonic ischemia 3 (2) 3 (2)
Cardiac insufﬁciency 0 2 (1)
Myocardial infarction 1 (1) 0
Peritonitis 1 (1) 0
Follow up 4 0 4
Respiratory failure 1
Renal insufﬁciency 1 0
Myocardial infarction 1 0
Rupture 1 0
Note. Values in parentheses are the 30 day values.
ECAR ¼ Endovasculaire ou Chirurgie dans les Anévrysmes aorto-
iliaques Rompus; EVAR ¼ endovascular aneurysm repair;
OSR ¼ open surgical repair; MOF ¼ multiorgan failure;
ARDS ¼ acute respiratory distress syndrome.
Table 3. Post-operative complications and features according to
groups.
Covariate EVAR
(n ¼ 56)
OSR
(n ¼ 51)
p
Post-operative death at 30 days 11 (19.6) 12 (24) .239
In hospital post-operative death 13 (23.2) 18 (35) .176
Death at 1 year 17 (30.3) 18 (35) .296
Severe post-operative
complicationsa
25 (44.6) 28 (54.9) .291
Myocardial infarction 2 (3.6) 1 (2.0)
Cardiac insufﬁciency 0 2 (4.0)
Hemodialysis/renal insufﬁciency 6 (10.7) 2 (3.9) .345
Colonic ischemia 5 (8.9) 11 (21.6) .071
Mesenteric ischemia 0 1 (2.0)
Peritonitis 1 (1.8) 0
Compartment syndrome 8 (14.3) 1 (2.0) .052
Major amputation 0 2 (4.0)
Pulmonary complications 8 (15.3) 18 (41.4) .012
Pulmonary embolism 1 (1.8) 0
Post-operative hemorrhage 0 1 (2.0)
Emboli/thrombosis 2 (3.6) 0
MOF 3 (5.4) 5 (9.8) .791
Sepsis 6 (10.7) 3 (5.9) .638
Mean post-operative
respiratory support, h (range)
59.3
(0e720.0)
180.3
(0e720.0)
.007
Re-intubation 45 (86.5) 29 (70.7) .061
Mean units used in
blood transfusion (range)
6.8
(0e25.0)
10.9
(0e53.0)
.024
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general anesthesia and eight under local anesthesia. Mean
duration of intervention was 194.3  153.7 minutes (range
60.0e1040.0 minutes). Forty-one patients (73.2%) were
treated by aorto-uni-iliac stent graft, 12 (22.6%) had a
bifurcated stent graft, and three (5.4%) had a stent graft
limited to the iliac artery. Devices used were Zenith (Cook)
(n ¼ 42; 75.0%), Talent (Medtronic) (n ¼ 9; 16.1%), Excluder
(WL Gore) (n ¼ 3; 5.3%), Anaconda (Vascutek, Inchinnan,
UK) (n ¼ 1; 1.8%), and Fluency (Bard, Tempe, AZ, USA)
(n ¼ 1, 1.8%). The IIA was embolized in eight patients, and
bridged by the iliac limb in 18 (one bilateral). Mean dura-
tion of ﬂuoroscopy was 31.2  27.4 minutes and the mean
volume of contrast used was 133.3  60.6 mL.
In one patient a right renal artery was covered by the
body of the stent graft, and in three patients polar renal
arteries were covered. In two patients with aorto-uni-iliac
stent graft, failure of the contralateral occluder stent graft
was treated by IIA ligation via a retroperitoneal approach. In
two patients endo-conversion by aorto-uni-iliac stent graft
was performed owing to the inability to insert the contra-
lateral limb. At the end of the procedure, endoleaks (one
proximal type 1 endoleak successfully treated by comple-
mentary stenting; one type 2 endoleak left untreated) were
observed in two patients (1.6%).Mean duration of stay
in ICU, days (range)
7 (1e30) 11.9
(0e33.0)
.012
Mean duration of in
hospital stay, days (mean)
14.3
(6.0e99.0)
17.1
(9.1e81.1)
.208
Note. Values are given as n (%) unless otherwise stated.
EVAR ¼ endovascular aneurysm repair; OSR ¼ open surgical
repair; MOF ¼ multi-organ failure; ICU ¼ intensive care unit.
a Eighty-nine severe post-operative complications (42 after EVAR,
47 after OSR) in 53 patients.Post-operative outcomes
The primary end point (i.e., mortality rate at 30 days) was
18.0% (n ¼ 10) in the EVAR group versus 25.0% (n ¼ 12) in
the OSR group (not signiﬁcant [ns]). The in hospital mor-
tality rate was 21.4% (n ¼ 12) in the EVAR group versus
35.0% (n ¼ 18) in the OSR group (ns). Causes of death
(n ¼ 35) are listed in Table 2. There was a trend towardsmore intra-operative deaths in the OSR group (4/51; 7.8%)
than in the EVAR group (1/56; 1.8%) (ns).
At 30 days, the incidence of major complications was
similar between the EVAR (n ¼ 25; 44.6%) and OSR (n ¼ 28;
54.9%) groups. Post-operative complications are listed in
Table 3.
Beyond 30 days, the requirements for hemodialysis were
not signiﬁcantly different (10.7% in the EVAR group versus
3.9% in the OSR group; p ¼ .345). Compartment syndrome
was observed in nine patients (8.4%; all treated by lapa-
rostomy): eight patients from the EVAR group (14.3%, four
of whom died) and one patient (2%, who died) from the
OSR group (p ¼ .052). Colonoscopy within the ﬁrst 48
hours, as recommended by the protocol, was performed in
34 patients (28.0%). Colonoscopies were not performed
because of rapid death (n ¼ 5), intra-operative colectomies
(n ¼ 3), and the absence of signs of colonic ischemia
(n ¼ 65). Colonoscopy was abnormal in ﬁve patients (8.9%)
in the EVAR group versus 11 (21.6%) in the OSR group
(p ¼ .049). In the EVAR group, four colonic resections were
performed and one patient survived; the last patient died
prior to intervention. In the OSR group, seven colonic re-
sections were performed, which led to three deaths; four
Figure 3. KaplaneMeier estimates for survival between open
surgical repair and endovascular aneurysm repair.
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vention). The mortality associated with colonic ischemia
was 8.4% of the overall population and 56.3% in patients
with colonic ischemia.
There were nine septic events: six patients in the EVAR
group (four cases of sepsis of femoro-femoral bypass, one
case of sepsis of an endoprosthesis, and one case of septic
hypogastric aneurysm) and three patients in the OSR group.
During the post-operative period, nine type 2 endoleaks
were diagnosed by CT scan.
The composite rate of severe complications and death at
30 days, 6 months, and 1 year was 39.3%, 46.0%, and 48.0%
in the EVAR group versus 41%, 47%, and 47% in the OSR
group (p ¼ .239, p ¼ .176, and p ¼ . 296), respectively.
The amount of total blood transfusion in the EVAR group
was signiﬁcantly lower than in the OSR group (6.8 vs. 10.8
units; p ¼ .024).
The duration of respiratory support was signiﬁcantly
lower in the EVAR group than in the OSR group (59.3 vs.
180.3 hours; p ¼ .007). There was a trend towards more
repeated intubation in the OSR group (29.3% vs. 13.5%;
p ¼ .061) and nearly 2.5 times more pulmonary complica-
tions in the OSR group (41.5% vs. 15.4%; p ¼ .005).
The mean duration of ICU stay was lower in the EVAR
group (7 vs. 11.9 days; p ¼ .012)
The median total hospital stay was 17.1 days in the OSR
group versus 14.3 days in the EVAR group (p ¼ .208).Long-term follow up
Mean duration of follow up was 231.8 days (range 31.0e
365.0 days). No patient was lost to follow up.
Long-term survival curves of patients randomized to
EVAR and OSR did not show any signiﬁcant difference be-
tween the two groups at 30 days and 1 year (Fig. 3).Most post-operative type 2 endoleaks resolved, but one
was treated by embolization at 3 months. Three additional
type 2 endoleaks were diagnosed on follow up CT scans:
two resolved spontaneously and one persisted without
signiﬁcant increase in AAA diameter. One aneurysm rupture
occurred 6 months after EVAR.
Morbidity indices
There was no signiﬁcant difference in IGSII score between
OSR and EVAR.
Univariate analysis identiﬁed factors inﬂuencing 30 day
survival: age, use of endoclamping, SBP, creatinine clear-
ance, bicarbonate, and Hardman index score. There was no
center effect. There were only four variables identiﬁed from
the multivariate analysis of factors inﬂuencing 30 day
mortality: hemoglobin, SBP, creatinine clearance, and
bicarbonate.
Hospitalization costs
The mean cost difference between EVAR (V7,087.5) and
OSR (V9,329.4) was V2,241.9 per patient. When adjusting
costs according to OSR case mix, there was still a difference
of V525.6 between EVAR (V8,803.8) and OSTR (V9,329.4).
DISCUSSION
This study illustrates that at least 32.8% of rAIAs are suitable
for EVAR, as it was assumed that all those who received
OSR not randomized in ECAR trial were unsuitable for EVAR.
The discrepancy between centers illustrates that some of
the patients not enrolled in the trial and treated by OSR
might have been suitable for EVAR (Fig. 2); however,
extrapolating the results to an unselected cohort of rAIAs is
not possible, as the reasons for non-inclusion could not be
documented extensively.
To date, three RCTs of EVAR vs. OSR for rAIA have been
reported. The ﬁrst, a small pilot trial in which unstable pa-
tients were excluded, failed to demonstrate beneﬁt of EVAR
over OSR in terms of mortality.11 The Dutch AJAX trial,
which enrolled 116 hemodynamically stable patients with
anatomy suitable for EVAR, also showed no difference in
mortality rates between EVAR and OSR (21% vs. 25%).12 In
the UK IMPROVE trial, 30 day mortality results showed no
difference between an endovascular strategy (patients un-
derwent urgent CT followed by EVAR whenever this mo-
dality was possible) and an open repair strategy (CT scan
optional) (35% vs. 37%).13
The ECAR trial was designed to avoid as many potential
biases as possible.
As imposing one procedure on a surgeon used to prac-
ticing another procedure would introduce a bias, randomi-
zation by week was chosen, synchronously for all centers.
This methodology has the advantage of facilitating planning
of the emergency teams. Previous studies have been carried
out according to this method, for example in comparing two
methods of resuscitation after heart failure.14
It is difﬁcult to randomize hemodynamically unstable
patients because of the variation in the deﬁnition of
A French Randomized Controlled Trial of Endovascular 309hemodynamic instability among different teams, which is
related to the subjectivity of the deﬁnition itself. Some
teams prefer a SBP as low as 50 mmHg without observing
any increase of end-organ injury,13 however most teams
believe that, to avoid widespread organ injury, SBP should
be kept >80 mmHg unassisted by catecholamines, to be
indicative of hemodynamic stability. In our experience, most
patients treated with OSR were turned down for EVAR
because of severe hemodynamic instability precluding CT
scan.5
CT scanning prior to enrolment is mandatory to ensure
the correct mortality and morbidity statistics of EVAR
treated rAIAs in order to achieve the following three facts.
The ﬁrst is to establish the diagnosis of rupture. The mor-
tality rate of acute non-ruptured AAAs, recently reported to
be 15.8%,15 is lower than for rAIA, explaining an apparently
low mortality in some series. The second is to exclude other
abdominal pathologies.16 Hypotension and symptoms of
pain may be confused with those of renal colic, diverticu-
litis, appendicitis, pancreatitis, bowel obstruction, bowel
ischemia, gastrointestinal hemorrhage (typically from an
ulcer), perforated duodenal or gastric ulcer, other aortic
emergencies (dissection, intramural hematoma) lumbar
compression fracture, and inferior wall myocardial infarc-
tion. The third is to allow pre-operative planning, that is,
suitability for EVAR and graft size. Unsuitable access or
inadequate graft landing zones may result in endoleak or
conversion to OSR, which in most studies is associated with
a higher mortality. Intra-operative calibration angiography
has been proposed to avoid pre-operative delay due to CT
scanning but fails to exclude other pathologies and is less
accurate in predicting the correct size of graft in elective
series. Thus, its reliability is questionable.
In this study, the selection criteria (i.e., both favorable
anatomy and hemodynamic stability) explain the fact that
the mortality rate after OSR (24.0%) is much lower than the
expected 40.0% mortality rate on which the study design
was based. Although the length of hospital stay of many
patients exceeded 30 days, owing to complications, 30 day
mortality, which is the reporting standard of most studies,
was kept as the primary study end point, while in hospital
mortality, and 6 month and 1 year mortality were secondary
end points: in this trial, the mortality rates were not
different between EVAR and OSR, both in intention-to-treat
and per-protocol analyses, as there was no crossover. This
ﬁnding is consistent with the results of previously published
RCTs but may be due to an overly optimistic power calcu-
lation for the trial. Meta-analysis of all the trials should be
the next step in producing high level evidence. However,
total respiratory support time, pulmonary complications
and abnormal colonoscopy rates, total blood transfusion,
and duration of ICU stay were signiﬁcantly lower in the
EVAR group, conﬁrming the suspicion that EVAR is less
invasive than OSR. This study also found that EVAR reduces
hospitalization costs: even if the cost of OSR compared with
EVAR is lower when adjusted to patient status, EVAR is a
cost-effective alternative to OSR. A prospective comparison
of actual costs of EVAR with the current Frenchreimbursement system is necessary to allow extrapolation
of the ﬁndings.
rAIA mortality is mostly related to patient status on
arrival. This study carries a “national” bias as a group of
“stable” patients would have arrived earlierdbut less sta-
bledin countries where the transport is performed by
paramedics. In France, most patients are transported in
dedicated ambulances where an anesthesiologist re-
suscitates the patient as well as possible and for as long as
necessary to avoid hemodynamic variations during trans-
port. This results in a loss of time to referral to a surgical
ward and may jeopardize the results. The fact that three out
of four parameters identiﬁed by multivariate analysis are
biological seems to conﬁrm this potential limitation of the
ﬁndings.
This study, as with other RCTs, conﬁrms that EVAR is
feasible in an emergency setting, with the same reliability
(i.e., only two endo-conversions to aorto-uni-iliac, and one
complementary stenting for intra-operative type 1a endo-
leak), and secondary endoleaks compare favorably with
EVAR performed in an elective setting.
Mortality remains a challenge of surgical treatment of
rAIA. EVAR is only a step towards simplifying the strategy
but does not signiﬁcantly improve the survival rate. Other
technical reﬁnements such as endoclamping,14 are currently
resulting in more stable patients receiving OSR or EVAR. The
key point is that endovascular methods are now part of the
strategy, and adopted by most teams. Although only 14.3%
of patients in the EVAR group were operated on under local
anesthesia, endoclamping, also performed under local
anesthesia, allows a smoother induction in cases where
general anesthesia is chosen.
Although the results do not allow EVAR to be advocated
as a ﬁrst line strategy for all suitable rAIAs, the authors are
comfortable proposing an algorithm of treatment where
endovascular techniques play a major role.CONCLUSION
As in previous RCTs, the current study fails to demonstrate a
mortality beneﬁt of EVAR over OSR in suitable rAIAs.
However, there is a trend towards lesser morbidity and
lower costs when EVAR is used as the primary procedure in
suitable patients. Pooling the data of the available RCTs may
conﬁrm this assertion. Endovascular management of
ruptured aneurysms (endoclamping as well as EVAR) must
now to be considered as major progress.CONFLICT OF INTEREST
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